Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats

Cardiovascular Research

Volumn 44, Issue 3, 1999, Pages 518-526

  Kobayashi, Naohiko ^a   Higashi, Teruo ^a   Hara, Kazuyoshi ^a   Shirataki, Hiromichi ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

ACE inhibitors; Gene expression; Heart failure; Nitric oxide; Remodelling

Indexed keywords

ANGIOTENSIN; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ENDOTHELIUM INJURY; GENE EXPRESSION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HISTOLOGY; HYPERTENSION; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SODIUM INTAKE; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOTTING, WESTERN; COLLAGEN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HYPERTENSION; IMIDAZOLES; IMIDAZOLIDINES; MALE; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, INBRED DAHL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VENTRICULAR REMODELING;

EID: 0033461195     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00237-0     Document Type: Article

References (57)

1. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989;38:1709-1715.
2. Paulus WJ. Endothelial control of vascular and myocardial function in heart failure. Cardiovasc Drugs Ther 1994;8:437-446.
3. Haywood GA, Tsao PS, von der Leyen HE et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-1094.
4. De Beider AJ, Radomski MW, Why HJF et al. Nitric oxide synthase activities in human myocardium. Lancet 1993;341:84-85.
5. Thoenes M, Forstermann U, Tracey WR et al. Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol 1996;28:165-169.
6. Scott AL, Chang RS, Lotti VJ, Siegl PK. Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heart. J Pharmacol Exp Ther 1992;261:931-935.
7. Moravec CS, Schluchter MD, Paranandi L et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 1990;82:1973-1984.
8. Llambi HG, Manni F, Padula PL, Carretero OA, Taquini CM. Myocardial contractility is modulated by angiotensin II via nitric oxide. Hypertension 1996;27(2):704-708.
9. Gertz EW. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog Exp Tumor Res 1972;16:242-260.
10. Shinbane JS, Wood MA, Jensen DN et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709-715.
11. Inoko M, Kihara Y, Morii I, Fujiwara H, Sasayama S. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. Am J Physiol 1994;267:H2471-H2482.
12. Inoko M, Kihara Y, Sasayama S. Neurohumoral factors during transition from left ventricular hypertrophy to failure in Dahl salt-sensitive rats. Biochem Biophys Res Commun 1995;206:814-820.
13. Kihara Y, Sasayama S. Transition from compensatory hypertrophy to dilated failing left ventricle in Dahl-Iwai salt-sensitive rats. Am J Hypertens 1997;10:78S-82S.
14. Kihara Y, Inoko M, Sasayama S. Changes of myocardial contractile state and the intracellular calcium transients during transitions to heart failure: studies in Dahl rat heart failure model. J Cardiac Failure 1996;2:S113-S120.
15. Benedict CR, Weiner DH, Johnstone DE et al. for the SOLVD investigators. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) registry. J Am Coll Cardiol 1993;22:146A-153A.
16. Weinberg EO, Schoen FJ, George D et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994;90:1410-1422.
17. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
18. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
19. Dahl LK, Heine MA, Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature 1962;194:480-482.
20. Iwai J, Heine MA. Dahl salt-sensitive rats and human essential hypertension. J Hypertens 1986;4(suppl):S29-S31.
21. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:345-354.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
23. Hattori Y, Gross SS. GTP cyclohydrolase I mRNA is induced by LPS in vascular smooth muscle: Characterization, sequence and relationship to nitric oxide synthase. Biochem Biophys Res Commun 1993;195:435-441.
24. Seki T, Naruse M, Naruse K et al. Gene expression of endothelial type isoform of nitric oxide synthase in various tissues of strokeprone spontaneously hypertensive rats. Hypertens Res 1997;20:43-49.
25. Nunokawa Y, Ishida N, Tanaka S. Cloning of inducible nitric oxide synthase in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1993;191:89-94.
26. Nicoletti A, Heudes D, Hinglais N et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995;26:101-111.
27. Terada Y, Tomita K, Nonoguchi H, Marumo F. Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. J Clin Invest 1992;90:659-665.
28. Hattori Y, Akimoto K, Murakami Y, Kasai K. Pyrrolidine dithiocarbamate inhibits cytokine-induced VCAM-1 gene expression in rat cardiac myocytes. Mol Cell Biochem 1997;177:177-181.
29. Kobayashi N, Kobayashi K, Hara K et al. Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Am J Hypertens 1999;12:483-491.
30. Kobayashi N, Yanaka H, Tojo A, Kobayashi K, Matsuoka H. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in chronic nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol 1999;34:173-181.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976;72:248-254.
32. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
33. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
34. Kobayashi N, Kobayashi K, Kouno K, Yagi S, Matsuoka H. Effect of benidipine on microvascular remodeling and coronary flow reserve in two-kidney one clip Goldblatt hypertension. J Hypertens 1997;15:1285-1294.
35. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992;105:575-580.
36. Balligand J, Ungureanu-Longroi D, Simmons WW et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. J Biol Chem 1994;269:27580-27588.
37. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure. Potentiation of β-adrenergic inotropic responsiveness. Circulation 1998;97:161-166.
38. Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation 1995;92:2683-2689.
39. Cachofeiro V, Sakakibara T, Nasjletti A. Kinin, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-145.
40. Takase H, Moreau P, Küng CF et al. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency: Effect of verapamil and trandolapril. Hypertension 1996;27:25-31.
41. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
42. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
43. Tojo A, Kobayashi N, Kimura K et al. Effects of antihypertensive drugs on nitric oxide synthase activity in rat kidney. Kidney Int 1996;49(suppl 55):S138-S140.
44. Erdös EG. Angiotensin converting enzyme and the change in our concept through the years. Hypertension 1990;26:363-370.
45. Giacomelli F, Anversa P, Wiener J. Effect of angiotensin-induced hypertension on rat coronary arteries and myocardium. Am J Pathol 1976;84:111-125.
46. Kato H, Suzuki H, Tajima S et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991;9:7-22.
47. Morgan HE, Baker KM. Cardiac hypertrophy, mechanical, neural and endocrine dependence. Circulation 1991;83:13-25.
48. Ishigai Y, Mori T, Ikeda T, Fukuzawa A, Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol 1997;273:H2659-H2663.
49. Hartman JC. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995;60:789-792.
50. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med 1991;325:293-302.
51. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med 1991;325:303-310.
52. Sharpe N, Smith H, Murphy J et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition. Lancet 1991;337:872-876.
53. Ogino K, Kato M, Noguchi N et al. Effects of enalapril on the exercise capacity and neurohumoral factors during exercise in patients with chronic heart failure. Cardiology 1997;88:6-13.
54. Narita H, Kaburaki M, Doi H et al. Prolonging action of imidapril on the lifespan expectancy of cardiomyopathic hamsters. J Cardiovasc Pharmacol 1996;27:861-871.
55. Ogiku N, Sumikawa H, Nishimura T, Narita H, Ishida R. Reduction of the mortality rate by imidapril in a small coronary artery disease model, (NZW×BXSB) F1 male mice. Jpn J Pharmacol 1994;64:129-133.
56. Schoelkens BA, Linz W, Lindpaintner K, Ganten D. Angiotensin deteriorates but bradykinin improves cardiac function following ischaemia in isolated rat hearts. J Hypertens 1987;5(suppl 5):S7-S9.
57. Weber KT, Sun Y, Tatwa LC, Cleutjens JP, Zhou G. Connective tissue and repair in the heart. Potential regulatory mechanisms. Ann New York Acad Sci 1995;752:286.